Navigation Links
Orexigen(R) Therapeutics Announces Third Quarter 2008 Financial Results
Date:11/6/2008

mulation work and consulting activities, as well as an increase in salaries and personnel related costs. In addition, general and administrative expenses increased approximately $944,000 due primarily to increases in stock-based compensation expense, facilities expenses and costs related to consulting activities.

Nine Months Ended September 30, 2008

For the nine months ended September 30, 2008, Orexigen reported a net loss of $71.1 million, or $2.12 per share attributable to common stockholders, as compared to a net loss of $38.4 million, or $2.40 per share attributable to common stockholders, for the comparable period in 2007.

Total operating expenses for the nine months ended September 30, 2008 were $72.8 million compared to $40.6 million for the comparable period in 2007. The increased operating expenses were due primarily to a $28.5 million increase in research and development expenses in connection with the Company's Contrave Phase 3 clinical trials, related proprietary product formulation work and consulting activities, as well as an increase in salaries and personnel related costs. In addition, general and administrative expenses increased by $3.6 million due primarily to increases in stock-based compensation expense, salaries and personnel related costs and facilities expenses.

"This has been a highly productive quarter for Orexigen," said Gary Tollefson, M.D., Ph.D., President and CEO. "We completed enrollment in our ZB-202 Phase 2b clinical trial for Empatic(TM), initiated the Phase 2 proof-of-concept clinical trials for OREX-003 and OREX-004 and had a significant presence at the recent Annual Scientific Meeting of the Obesity Society, including reviewing important results from our lead obesity programs, Contrave and Empatic. We are eagerly awaiting data from our Contrave Phase 3 clinical trial, NB-302, and believe that we remain on track for an NDA filing for Contrave in late 2009."

Recent Highlights

-- Orexigen i
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain
2. Orexigen(R) Therapeutics Appoints Dennis Kim, M.D., as Senior Vice President, Head of Obesity and Metabolic Disorders
3. Orexigen(R) Therapeutics to Present at Upcoming Investor Conferences
4. Orexigen(R) Therapeutics Schedules Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2008
5. OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003
6. CV Therapeutics Reports 2008 Third Quarter Financial Results
7. Cell Therapeutics, Inc. (CTI) to Report 2008 Third Quarter Financial Results on November 7
8. According to AlphaDetail, Inc. Merck and Tibotec Therapeutics Lead Among Infectious Disease Specialists
9. Amicus Therapeutics Announces Third Quarter 2008 Financial Results
10. Nile Therapeutics to Present at Two Upcoming Investor Conferences
11. Arno Therapeutics to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... Inc. (TSXV: BRM) ("Biorem" or "the Company") today announced its results ... complete second quarter financial statements and MD&A have been filed on ... per shareThree-months ended , Six -months endedJune 30 , June 30 ... 2014 Revenue , 4,709 , 2,459 ... 1,656 , 56 , 3,188 , ...
(Date:8/27/2015)... PARK, N.C. , Aug. 27, 2015 /PRNewswire/ ... the decision by FedEx, UPS and The US ... certain biological specimens classified as ,select agents, by ... long history of handling these sensitive shipments. ... of global transportation regulations, trained and certified personnel ...
(Date:8/26/2015)... ... August 26, 2015 , ... Lee Biosolutions, a global biotech ... manufacture of highly valued cardiac markers used in early detection of heart disease ... chemistry has led to the development and commercialization of important cardiac biomarkers used ...
(Date:8/26/2015)... -- China Cord Blood Corporation (NYSE: CO ) ... of cord blood collection, laboratory testing, hematopoietic stem cell ... the Company has been informed that Magnum Opus 2 ... Mr. Yuen Kam, chairman of the board of directors ... "Shares") of  Excellent China Healthcare Investment Limited ("KKR SPV") ...
Breaking Biology Technology:BIOREM Reports $718,000 Net Earnings for the Second Quarter 2BIOREM Reports $718,000 Net Earnings for the Second Quarter 3Marken Ensures Safe Transportation Of Select Agents And Toxins 2Lee Biosolutions Announces Increased Investment in the Development and Manufacturing of Biomarkers Used in Early Detection Of Heart Disease 2China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 2China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 3
... BioSpace, the leading biotech,job board and life ... and pharmaceutical job seekers to the first BioSpace ... The BioSpace Career Fair attracted a steady flow ... from around southern California. The event offered a ...
... of ... DEERFIELD, Ill., Feb. 11 Baxter Healthcare,Corporation is providing ... 10 and 30mL multi-dose vial voluntary recall of,nine lots, which ... in reports of adverse reactions that may be associated with ...
... Phlo,Corporation,s ("Phlo"") (OTC: PHLC) press release of December 27, ... City Account,Base," an affiliate of Phlo (the "Company") announced ... has sold and delivered,AQISS(TM) to the following initial retail ... roll out. AQISS(TM) is currently available for sale to ...
Cached Biology Technology:BioSpace Career Fair in San Diego Draws Record Number of Bioscience Candidates 2Baxter Provides Update on Heparin Reactions 2Baxter Provides Update on Heparin Reactions 3Phlo Affiliate Reports Progress in New York City Metropolitan Area Roll-Out 2
(Date:8/24/2015)... TOWN, South Africa , August 24, 2015 ... Germany ,s largest biometrics manufacturer DERMALOG and ... with the "2015 African Biometrics Company of the Year ... in Nigeria .   -Cross ... and http://www.presseportal.de/nr/8896 - On Thursday evening, ...
(Date:8/20/2015)... CLARA, Calif. , Aug. 20, 2015 /PRNewswire/ ... company focused on improving the user experience and ... and vision technologies, today announced that its ... voice biometric authentication software to be FIDO ... tested TrulySecure for compliance with the FIDO UAF ...
(Date:8/18/2015)... , Aug. 18, 2015  Navitas today ... contributor to the Submission Content Management webinar ... a non-profit forum. Dedicated to the Implementation of ... neutral platform for industry, vendors, health authorities, ... and work towards a standard method of ...
Breaking Biology News(10 mins):Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 2Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 3TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 2TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 3TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 4TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 5Navitas, a Key Contributor in IRISS Forum Webinar 2Navitas, a Key Contributor in IRISS Forum Webinar 3
... RECAN has developed a range of unique and highly ... in the blood which counteract bacteria, viruses or cancerous ... of recombinant proteins which are important components of cellular ... in immunisation and experimental studies. A further key advance ...
... DURHAM, N.C. A $10.2 million commitment from the ... Center (TCTC) will advance Duke Medicine,s pioneering cell therapy ... cancer, cerebral palsy, stroke and brain injuries suffered at ... Chancellor for Health Affairs, Duke University, and Chief Executive ...
... 3,000-year record from 52 of the world,s oldest trees shows ... from 800 to 1300, according to new research. ... scars on ancient giant sequoia trees, Sequoiadendron giganteum , ... sequoias can live more than 3,000 years. "It,s ...
Cached Biology News:Manufacturing antibodies 2Manufacturing antibodies 3Robertson Foundation donates $10.2 million for Duke Cell Therapy Center 2Robertson Foundation donates $10.2 million for Duke Cell Therapy Center 3Giant sequoias yield longest fire history from tree rings 2Giant sequoias yield longest fire history from tree rings 3
Contains L-glutamine...
... The PhosphatidylEthanolamine-Binding Protein (PEBP) does not ... protease inhibitors. PEBP is expressed ... testis, ovary, muscle, and stomach. ... in is exerting inhibitory activity against ...
...
Highly sensive assay for detecting apoptosis in living cells. See detailed descriptions above in K250-25....
Biology Products: